|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CRKL |
Gene summary for CRKL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CRKL | Gene ID | 1399 |
| Gene name | CRK like proto-oncogene, adaptor protein | |
| Gene Alias | CRKL | |
| Cytomap | 22q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P46109 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1399 | CRKL | LZE4T | Human | Esophagus | ESCC | 1.21e-12 | 1.74e-01 | 0.0811 |
| 1399 | CRKL | LZE5T | Human | Esophagus | ESCC | 5.49e-04 | 5.45e-02 | 0.0514 |
| 1399 | CRKL | LZE7T | Human | Esophagus | ESCC | 4.93e-06 | 1.04e-01 | 0.0667 |
| 1399 | CRKL | LZE8T | Human | Esophagus | ESCC | 3.80e-04 | -4.12e-02 | 0.067 |
| 1399 | CRKL | LZE20T | Human | Esophagus | ESCC | 2.20e-02 | -1.13e-01 | 0.0662 |
| 1399 | CRKL | LZE24T | Human | Esophagus | ESCC | 5.99e-11 | 2.82e-01 | 0.0596 |
| 1399 | CRKL | LZE21T | Human | Esophagus | ESCC | 1.35e-03 | 1.69e-01 | 0.0655 |
| 1399 | CRKL | LZE6T | Human | Esophagus | ESCC | 7.03e-05 | 2.27e-02 | 0.0845 |
| 1399 | CRKL | P1T-E | Human | Esophagus | ESCC | 3.31e-05 | 3.44e-01 | 0.0875 |
| 1399 | CRKL | P2T-E | Human | Esophagus | ESCC | 1.53e-17 | 2.24e-01 | 0.1177 |
| 1399 | CRKL | P4T-E | Human | Esophagus | ESCC | 8.39e-16 | 4.03e-01 | 0.1323 |
| 1399 | CRKL | P5T-E | Human | Esophagus | ESCC | 2.57e-27 | 3.03e-01 | 0.1327 |
| 1399 | CRKL | P8T-E | Human | Esophagus | ESCC | 1.17e-16 | 1.41e-01 | 0.0889 |
| 1399 | CRKL | P9T-E | Human | Esophagus | ESCC | 1.41e-12 | 2.98e-01 | 0.1131 |
| 1399 | CRKL | P10T-E | Human | Esophagus | ESCC | 7.24e-25 | 4.57e-01 | 0.116 |
| 1399 | CRKL | P11T-E | Human | Esophagus | ESCC | 2.64e-08 | 4.98e-01 | 0.1426 |
| 1399 | CRKL | P12T-E | Human | Esophagus | ESCC | 1.55e-22 | 2.81e-01 | 0.1122 |
| 1399 | CRKL | P15T-E | Human | Esophagus | ESCC | 4.31e-10 | 2.79e-01 | 0.1149 |
| 1399 | CRKL | P16T-E | Human | Esophagus | ESCC | 1.64e-20 | 2.33e-01 | 0.1153 |
| 1399 | CRKL | P17T-E | Human | Esophagus | ESCC | 9.99e-05 | 2.32e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000268510 | Oral cavity | OSCC | regulation of leukocyte migration | 108/7305 | 210/18723 | 1.63e-04 | 1.13e-03 | 108 |
| GO:0071887 | Oral cavity | OSCC | leukocyte apoptotic process | 60/7305 | 106/18723 | 1.78e-04 | 1.21e-03 | 60 |
| GO:00508527 | Oral cavity | OSCC | T cell receptor signaling pathway | 68/7305 | 123/18723 | 1.80e-04 | 1.22e-03 | 68 |
| GO:001097510 | Oral cavity | OSCC | regulation of neuron projection development | 210/7305 | 445/18723 | 2.35e-04 | 1.52e-03 | 210 |
| GO:005090010 | Oral cavity | OSCC | leukocyte migration | 176/7305 | 369/18723 | 3.80e-04 | 2.31e-03 | 176 |
| GO:190002418 | Oral cavity | OSCC | regulation of substrate adhesion-dependent cell spreading | 35/7305 | 57/18723 | 5.10e-04 | 2.98e-03 | 35 |
| GO:003444618 | Oral cavity | OSCC | substrate adhesion-dependent cell spreading | 59/7305 | 108/18723 | 7.01e-04 | 3.89e-03 | 59 |
| GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
| GO:0033628 | Oral cavity | OSCC | regulation of cell adhesion mediated by integrin | 30/7305 | 48/18723 | 8.31e-04 | 4.41e-03 | 30 |
| GO:00016558 | Oral cavity | OSCC | urogenital system development | 160/7305 | 338/18723 | 1.03e-03 | 5.31e-03 | 160 |
| GO:00483843 | Oral cavity | OSCC | retinoic acid receptor signaling pathway | 21/7305 | 31/18723 | 1.13e-03 | 5.75e-03 | 21 |
| GO:00017831 | Oral cavity | OSCC | B cell apoptotic process | 17/7305 | 24/18723 | 1.59e-03 | 7.56e-03 | 17 |
| GO:00603269 | Oral cavity | OSCC | cell chemotaxis | 146/7305 | 310/18723 | 2.13e-03 | 9.80e-03 | 146 |
| GO:00716758 | Oral cavity | OSCC | regulation of mononuclear cell migration | 60/7305 | 115/18723 | 2.78e-03 | 1.21e-02 | 60 |
| GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
| GO:0070227 | Oral cavity | OSCC | lymphocyte apoptotic process | 40/7305 | 72/18723 | 3.21e-03 | 1.38e-02 | 40 |
| GO:001076918 | Oral cavity | OSCC | regulation of cell morphogenesis involved in differentiation | 51/7305 | 96/18723 | 3.43e-03 | 1.45e-02 | 51 |
| GO:00726783 | Oral cavity | OSCC | T cell migration | 37/7305 | 66/18723 | 3.66e-03 | 1.51e-02 | 37 |
| GO:003432916 | Oral cavity | OSCC | cell junction assembly | 190/7305 | 420/18723 | 4.99e-03 | 1.96e-02 | 190 |
| GO:20004013 | Oral cavity | OSCC | regulation of lymphocyte migration | 34/7305 | 61/18723 | 5.90e-03 | 2.25e-02 | 34 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05170210 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
| hsa0513526 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
| hsa0522020 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
| hsa05163210 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
| hsa05100211 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
| hsa0521118 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
| hsa0472225 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
| hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
| hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
| hsa0466620 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
| hsa0401218 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
| hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0517038 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
| hsa05135111 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
| hsa05220110 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
| hsa0516338 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
| hsa05100310 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
| hsa0521119 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
| Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CRKL | SNV | Missense_Mutation | c.74N>G | p.Gln25Arg | p.Q25R | P46109 | protein_coding | tolerated(0.12) | benign(0.219) | TCGA-C8-A130-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CRKL | SNV | Missense_Mutation | c.343N>T | p.Ala115Ser | p.A115S | P46109 | protein_coding | tolerated(0.45) | benign(0.011) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CRKL | SNV | Missense_Mutation | c.614N>G | p.His205Arg | p.H205R | P46109 | protein_coding | tolerated(0.67) | probably_damaging(0.95) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CRKL | SNV | Missense_Mutation | novel | c.845N>A | p.Arg282His | p.R282H | P46109 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CRKL | SNV | Missense_Mutation | c.434N>C | p.Lys145Thr | p.K145T | P46109 | protein_coding | deleterious(0.03) | probably_damaging(0.995) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| CRKL | SNV | Missense_Mutation | novel | c.313N>C | p.Tyr105His | p.Y105H | P46109 | protein_coding | tolerated(0.54) | benign(0.193) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
| CRKL | SNV | Missense_Mutation | c.343G>A | p.Ala115Thr | p.A115T | P46109 | protein_coding | tolerated(0.32) | benign(0.031) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| CRKL | SNV | Missense_Mutation | c.136N>T | p.Gly46Trp | p.G46W | P46109 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CRKL | SNV | Missense_Mutation | c.832N>A | p.Glu278Lys | p.E278K | P46109 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CRKL | SNV | Missense_Mutation | c.671N>T | p.Gly224Val | p.G224V | P46109 | protein_coding | tolerated(0.15) | possibly_damaging(0.619) | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1399 | CRKL | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE | GEFITINIB | GEFITINIB | 22586683 | |
| 1399 | CRKL | CLINICALLY ACTIONABLE, DRUG RESISTANCE, KINASE | DASATINIB | DASATINIB | 22591714 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |